1g Vial - Powder for Injection
Box of 10’s (10ml single dose vial)
Cefoxitin for Injection, USP contains cefoxitin sodium a semi-synthetic, broad-spectrum cephalosporin antibiotic for parenteral administration. It is derived from cephalosporin C, which is produced by Cephalosporium Acremonium. It is the sodium salt of 3-(hydroxymethyl)-7-methoxy-8-oxo-7-[2-(2-thienyl)acetamido]-5-thia-1-azabicyclo [4.2.0] oct-2-ene-2-carboxylate carbamate (ester). The molecular formula is C16H16N3NaO7S2, Cefoxitin for Injection, USP contains approximately 53.8 mg (2.3 milliequivalents) of sodium per gram of cefoxitin activity. Solutions of Cefoxitin for Injection, USP range from colorless to light amber in color. The pH of freshly constituted solutions usually ranges from 4.2 to 7.0. Each conventional vial contains sterile cefoxitin sodium, USP equivalent to 1 or 2 g cefoxitin.
For IM injection: 1g vial should be constituted with 2ml of 0.5% lidocaine hydrochloride solution.
For intermittent intraveneous administration: 1g vial should be constituted with 10ml of sterile water for injection. The constituted solution can be injected over a period of 3 to 5minutes.
Fot Intraveneous infusion: 1g vial should be constituted and dissolved in 50 or 100ml of 0.9% Sodium Chloride Injection or 10% Dextrose injection.
These constituted solutions maintain satisfactory potency for 6 hours at room temperature or for 24 hours under refrigeration (2-8°C), no freezing.
Cefoxitin Sodium (HOXIT) may be administered intramuscularly or intravenously. For singe use only. Discard any remaining portion.
For the treatment and prophylaxis of anaerobic and mixed bacterial infections, especially intra-abdominal and pelvic infections. Indications include endometritis (prophylaxis at ceasarian section), pelvic inflammatory disease and surgical infection (prophylaxis).It may also be used in the treatment of gonorrhea and urinary tract infection.
HOXIT is contraindicated in patients who have shown hypersensitivity to cefoxitin and the cephalosporin group of antibiotics.
WARNING AND PRECAUTION USE
The total daily dose should be reduced when HOXIT is administered to patients with renal insufficiency. Antibiotics (including cephalosporin) should be prescribed with caution in individuals with a history of gastrointestinal disease, particularly colitis.
Increased nephrotoxicity has been reported following concomitant administration of cephalosporin and amninoglycoside antibiotics.
There are no adequate and well-controlled studies in pregnant women. Hoxit should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
HOXIT is excreted in human milk in low concentrations. Caution should be exercised when HOXIT is administered to a nursing woman.
Safety and efficacy in pediatric patients from birth to three months of age have not yet been established. In pediatric patients three months of age and older higher doses of HOXIT have been associated with an increased incidence of eosinophilia and elevated SGOT.
No overall differences in safety and effectiveness were observed between older and younger subjects, but greater sensitivity of some older individuals cannot be ruled out. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.
DOSAGE AND ADMINISTRATION
Cefoxitin Sodium (HOXIT) may be administered intramuscularly or intraveneously. For single use only.
Hoxit is generally well-tolerated. The most common adverse reactions have been local reactions following intravenous or intramuscular injection. Other adverse reactions have been encountered infrequently.
Store at temperature not exceeding 30°C.